---
figid: PMC10312032__IENZ_A_2225800_F0002_C
pmcid: PMC10312032
image_filename: IENZ_A_2225800_F0002_C.jpg
figure_link: /pmc/articles/PMC10312032/figure/F0002/
number: Figure 2
figure_title: ''
caption: 'KP putative targets for drug development. TDO: tryptophan 2,3-dioxygenase;
  IDO1: indoleamine 2, 3 - dioxygenases; KYN: kynurenine; KYNA: kynurenic acid; AA:
  Anthranilic acid; KATs:kynurenine aminotransferase; KMO: kynurenine - 3 - monooxygenase;
  3 - HAA: 3-hydroxyanthranilic acid; 3-HAO: 3,4-dioxygenase of 3-hydroxyanthranilic
  acid; 3-HK: 3-hydroxyuric acid; NAD +: nicotinamide adenine dinucleotide; PicA:
  picolinic acid; QUIN: quinone; XA: xanthine acid; ACMS: aminocarboxymuconate - semialdehyde;
  AMS: 2-aminomuconic 6-semialdehyde.'
article_title: Research progress on the kynurenine pathway in the prevention and treatment
  of Parkinson’s disease.
citation: Ping Chen, et al. J Enzyme Inhib Med Chem. 2023;38(1):2225800.
year: '2023'

doi: 10.1080/14756366.2023.2225800
journal_title: Journal of Enzyme Inhibition and Medicinal Chemistry
journal_nlm_ta: J Enzyme Inhib Med Chem
publisher_name: Taylor & Francis

keywords:
- Parkinson’s disease
- kynurenine
- kynurenic acid
- quinolinic acid

---
